Cancer Cachexia Recast as Neuro-Metabolic Disorder

New research links cancer cachexia to disrupted brain–liver signalling through the vagus nerve, recasting cachexia as a neuro-metabolic disorder. The update is relevant due to the proposed mechanism involving tumour-driven inflammation, liver metabolic reprogramming, and experimental neuro-modulation/liver-directed therapy possibilities.

Cancer Cachexia :

Dimension	Key Details
Definition	Complex, chronic metabolic syndrome associated with cancer.
Prevalence	80% of patients with advanced cancers; accounts for a sizeable fraction of cancer deaths.
Distinction from starvation	Increased energy expenditure and metabolic breakdown of muscle and fat driven by tumour–host biology.
Symptoms	Comprises persistent loss of body weight; loss of appetite (anorexia); progressive muscle wasting and weakness; reduced response to chemotherapy and radiotherapy.
Tumour-driven inflammation	Regulates disruption of normal brain–liver nerve signalling through the vagus nerve.
Liver metabolic reprogramming	Altered neural signals that suppress HNF4α (a key regulator of liver metabolism), leading to appetite loss, systemic inflammation, and muscle wasting.
Progression stages	Early metabolic imbalance with appetite loss; progresses into liver metabolic dysfunction; systemic inflammation and muscle breakdown; advanced wasting with severe loss of weight and strength.
Diagnosis	Regular monitoring of body weight with assessment of muscle mass and strength; evaluation of appetite and nutritional status; metabolic and biochemical assessment.
Treatment approach	Emphasises early recognition and integrated, whole-patient care using combined strategies, including anti-inflammatory support, targeted nutrition, and feasible physical activity to preserve muscle and function.
New treatment possibilities	Explores neuromodulation to correct abnormal vagus nerve signalling and liver-targeted therapies restoring metabolic pathways, both shown in preclinical studies to reduce weight and muscle loss.